Fonar Corp (FONR)
16.86
+0.67
(+4.14%)
USD |
NASDAQ |
Apr 25, 16:00
16.80
-0.06
(-0.36%)
After-Hours: 20:00
Fonar SG&A Expense (Quarterly): 5.587M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 5.587M |
September 30, 2023 | 4.866M |
June 30, 2023 | 9.317M |
March 31, 2023 | 7.143M |
December 31, 2022 | 6.598M |
September 30, 2022 | 6.334M |
June 30, 2022 | 7.585M |
March 31, 2022 | 6.068M |
December 31, 2021 | 4.77M |
September 30, 2021 | 5.09M |
June 30, 2021 | 7.922M |
March 31, 2021 | 6.114M |
December 31, 2020 | 4.541M |
September 30, 2020 | 6.163M |
June 30, 2020 | 11.03M |
March 31, 2020 | 7.224M |
December 31, 2019 | 4.163M |
September 30, 2019 | 4.294M |
June 30, 2019 | 6.788M |
March 31, 2019 | 4.604M |
December 31, 2018 | 3.61M |
September 30, 2018 | 4.259M |
June 30, 2018 | 5.226M |
March 31, 2018 | 5.533M |
December 31, 2017 | 3.286M |
Date | Value |
---|---|
September 30, 2017 | 4.081M |
June 30, 2017 | 6.790M |
March 31, 2017 | 4.483M |
December 31, 2016 | 4.069M |
September 30, 2016 | 4.065M |
June 30, 2016 | 6.385M |
March 31, 2016 | 4.063M |
December 31, 2015 | 3.869M |
September 30, 2015 | 4.193M |
June 30, 2015 | 6.340M |
March 31, 2015 | 3.706M |
December 31, 2014 | 3.824M |
September 30, 2014 | 3.578M |
June 30, 2014 | 6.561M |
March 31, 2014 | 3.935M |
December 31, 2013 | 4.352M |
September 30, 2013 | 3.737M |
June 30, 2013 | 4.164M |
March 31, 2013 | 3.774M |
December 31, 2012 | 2.352M |
September 30, 2012 | 2.212M |
June 30, 2012 | 2.488M |
March 31, 2012 | 2.224M |
December 31, 2011 | 1.995M |
September 30, 2011 | 2.043M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
4.163M
Minimum
Dec 2019
11.03M
Maximum
Jun 2020
6.400M
Average
6.163M
Median
Sep 2020
SG&A Expense (Quarterly) Benchmarks
XWELL Inc | 6.392M |
ProPhase Labs Inc | 8.022M |
Applied DNA Sciences Inc | 3.084M |
Veracyte Inc | 48.21M |
OncoCyte Corp | 2.391M |